Wells Fargo & Company Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price

Key Points

• Wells Fargo raised its PTC Therapeutics price target to $112 from $109 and maintained an “overweight” rating, implying roughly 79% upside from the $62.40 share price.
• Analyst sentiment remains positive overall, with a “Moderate Buy” consensus rating and an average target price of $95.29, although ratings range from Strong Buy to Sell.
• PTC reported third-quarter revenue of about $358 million, up 69.6% year over year and above estimates, but posted a GAAP loss of $0.62 per share; management raised its 2026 revenue outlook to $1.29 billion-$1.32 billion.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) had its price target increased by equities researchers at Wells Fargo & Company from $109.00 to $112.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price target would indicate a potential upside of 79.49% from the company's current price.

Several other equities research analysts have also recently commented on the company. Royal Bank Of Canada increased their price objective on PTC Therapeutics from $75.00 to $77.00 and gave the company a "sector perform" rating in a research report on Friday. Cantor Fitzgerald lifted their target price on PTC Therapeutics from $130.00 to $137.00 and gave the stock an "overweight" rating in a report on Tuesday, September 22nd. Zacks Research lowered PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 6th. Barclays upped their target price on PTC Therapeutics from $120.00 to $122.00 and gave the stock an "overweight" rating in a report on Friday, August 14th. Finally, Morgan Stanley increased their price objective on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $95.29.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT traded down $2.06 during midday trading on Friday, hitting $62.40. The stock had a trading volume of 963,860 shares, compared to its average volume of 1,345,500. The firm has a market cap of $5.21 billion, a P/E ratio of -107.21, a price-to-earnings-growth ratio of 1.90 and a beta of 0.49. PTC Therapeutics has a fifty-two week low of $58.80 and a fifty-two week high of $90.87. The company's 50-day simple moving average is $65.57 and its 200 day simple moving average is $70.87.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.76). The business had revenue of $357.81 million during the quarter, compared to analysts' expectations of $306.43 million. PTC Therapeutics's quarterly revenue was up 69.6% on a year-over-year basis. During the same quarter last year, the company posted $0.20 earnings per share. Equities analysts expect that PTC Therapeutics will post 1.19 EPS for the current fiscal year.

Insider Activity at PTC Therapeutics

In other news, Director Michael Schmertzler sold 2,500 shares of PTC Therapeutics stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a total transaction of $149,025.00. Following the transaction, the director owned 1,291,594 shares in the company, valued at $76,991,918.34. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 435 shares of the business's stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the transaction, the vice president owned 105,272 shares in the company, valued at $6,754,251.52. The trade was a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 77,370 shares of company stock valued at $5,322,261. 5.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PTCT. EverSource Wealth Advisors LLC increased its stake in PTC Therapeutics by 16.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 151 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in PTC Therapeutics by 1.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,730 shares of the biopharmaceutical company's stock valued at $1,120,000 after purchasing an additional 237 shares during the period. PNC Financial Services Group Inc. raised its holdings in PTC Therapeutics by 8.5% in the first quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 244 shares during the period. State of Wyoming grew its position in PTC Therapeutics by 15.3% in the third quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company's stock valued at $127,000 after acquiring an additional 260 shares in the last quarter. Finally, Vise Technologies Inc. grew its stake in PTC Therapeutics by 3.1% during the 3rd quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company's stock valued at $572,000 after purchasing an additional 266 shares in the last quarter.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year and above the roughly $306 million consensus estimate. Product revenue was $276 million, led by Sephience (sepiapterin), which generated $182 million as U.S. adoption and international expansion continued. PTC Therapeutics Third-Quarter Results
• Positive Sentiment: Management raised its 2026 outlook, now expecting total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. The upgrade signals confidence in Sephience’s commercial momentum and the broader product portfolio. PTC Therapeutics Raises 2026 Outlook
• Positive Sentiment: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its Biologics License Application submission in the fourth quarter of 2026. The deal adds a potential late-stage growth asset, although regulatory and development execution remain important risks. PTC Corporate Update
• Negative Sentiment: Reported profitability was mixed. PTC posted a GAAP loss of $0.62 per share, well below the consensus estimate for $0.14 of earnings, even though an adjusted earnings measure cited by Zacks was $0.61 per share and above estimates. The conflicting measures may have contributed to investor caution. PTC Swings to Third-Quarter Loss
• Neutral Sentiment: The earnings call focused on Sephience’s launch trajectory, global expansion, the ST-920 acquisition and the updated 2026 outlook. Investors will likely monitor whether revenue growth translates into sustainable earnings and cash flow. PTC Q3 2026 Earnings Call Transcript

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company's commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.